MENLO PARK, Calif., May 27, 2026
Subtle Medical, a leading developer of AI-powered medical imaging software, has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for SubtleHD™(PET), the company’s next-generation artificial intelligence solution designed to accelerate and enhance positron emission tomography (PET) imaging workflows across PET/CT and PET/MR systems. The newly cleared software is engineered to support all FDA-approved radiotracers while enabling up to 75% faster PET imaging on existing scanner infrastructure, a major advancement as healthcare systems face increasing demand for molecular imaging services worldwide.
The FDA clearance significantly expands Subtle Medical’s reach within the rapidly growing PET imaging market, particularly among healthcare providers utilizing advanced radiotracers, theranostic imaging programs, and integrated molecular imaging platforms. Industry estimates indicate that approximately 4.5 million PET scans are performed globally each year, with procedure volumes expected to rise substantially over the coming years due to expanding oncology applications, precision medicine initiatives, and next-generation theranostic therapies. Healthcare providers are increasingly seeking scalable imaging technologies capable of improving operational efficiency, increasing scanner throughput, and expanding patient access without requiring costly hardware replacement programs.
AI-Powered PET Imaging Enhances Speed and Accuracy
SubtleHD™(PET) builds on the company’s earlier SubtlePET™ platform and incorporates a new state-of-the-art artificial intelligence model architecture designed to improve PET image quality, image reconstruction consistency, and quantitative imaging performance. According to Subtle Medical, the software delivers enhanced image acceleration capabilities while also improving SUVmax quantitation accuracy, an important metric used by radiologists and oncologists to evaluate metabolic activity in cancer imaging.
The software was validated across a broad range of accelerated low-count PET acquisitions and allows radiologists to customize denoising levels according to clinical preferences and imaging requirements. In addition, the solution leverages anatomical CT data to further enhance PET image reconstruction quality and improve quantitative consistency across imaging studies. The company stated that the platform supports all FDA-approved radiotracers, including emerging molecular imaging agents extending beyond conventional 18F-FDG imaging applications.
Advertisement
Ajit Shankaranarayanan, a senior executive at Subtle Medical, stated that healthcare providers worldwide continue facing operational challenges related to scanner capacity limitations, long PET scan durations, and rising imaging demand. He emphasized that SubtleHD™(PET) was developed to help imaging providers improve throughput, increase patient access, maximize utilization of existing PET infrastructure, and deliver faster, more comfortable imaging experiences for patients.
Faster Imaging Could Improve Patient Access and Workflow Efficiency
Shorter PET imaging procedures may offer significant clinical and operational benefits across healthcare systems. Patients undergoing PET scans — particularly oncology patients, elderly individuals, pediatric populations, and critically ill patients — often struggle with lengthy imaging sessions that may lead to discomfort, motion artifacts, and workflow inefficiencies. By reducing scan duration by up to 75%, SubtleHD™(PET) may help improve overall patient experience while increasing daily scanner utilization and appointment availability.
For imaging centers and hospitals, faster PET imaging may substantially improve operational performance by creating additional scan slots, increasing revenue opportunities, reducing scheduling backlogs, and supporting higher patient volumes without purchasing additional imaging equipment. Industry analysts believe AI-powered imaging acceleration technologies may become increasingly important as molecular imaging demand continues expanding due to growth in oncology diagnostics, theranostics, neurology, and cardiovascular imaging.
Subtle Medical noted that the new FDA clearance also expands compatibility for institutions operating cyclotron infrastructure and advanced radiotracer production programs, areas expected to see increasing growth as personalized medicine and targeted radionuclide therapies continue advancing.
Subtle Medical Expands AI Imaging Platform Strategy
SubtleHD™(PET) forms part of Subtle Medical’s broader multi-modality AI imaging portfolio spanning MRI, PET, and CT imaging applications. The company stated that healthcare systems are increasingly searching for enterprise-scale AI platforms capable of integrating across existing imaging infrastructure while standardizing image quality, improving efficiency, and accelerating diagnostic workflows.
Subtle Medical’s long-term strategy centers on development of a unified AI Imaging Hub designed to accelerate, enhance, and organize imaging workflows across scanners, imaging modalities, and healthcare networks. The company currently has AI imaging solutions deployed across more than 1,300 scanners worldwide, supporting radiology departments and imaging centers in improving image quality and operational performance without requiring major hardware upgrades.
Industry experts believe AI-driven imaging acceleration and enhancement technologies may become a major component of future radiology workflows as healthcare systems seek scalable solutions capable of managing increasing imaging demand while improving patient care outcomes and operational sustainability.
Source: Subtle Medical press release
